Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice

Obesity

Volumn 22, Issue 5, 2014, Pages 1287-1295

  Skowronski, Alicja A ^a   Morabito, Michael V ^a   Mueller, Bridget R ^a   Lee, Samuel ^a   Hjorth, Stephan ^b   Lehmann, Anders ^b   Watanabe, Kazuhisa ^a   Zeltser, Lori M ^a   Ravussin, Yann ^a   Rosenbaum, Michael ^a   Leduc, Charles A ^a   Leibel, Rudolph L ^a  

^a Department of Pediatrics Columbia University College of Physicians and Surgeons ^*  (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2820; GLUCOSE; INSULIN; LEPTIN; MELANOCORTIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; HORMONE; MC4R PROTEIN, MOUSE; MELANOCORTIN 4 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CALORIMETRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENERGY EXPENDITURE; FAT MASS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; TREATMENT DURATION; WEIGHT CONTROL; WEIGHT REDUCTION; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; CALORIC RESTRICTION; DRUG EFFECTS; ENERGY METABOLISM; LIPID DIET; METABOLISM; MOUSE MUTANT;

ANIMALIA; MUS;

ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; CALORIC RESTRICTION; CALORIMETRY, INDIRECT; DIET, HIGH-FAT; ENERGY METABOLISM; HORMONES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; WEIGHT LOSS;

EID: 84899961471     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20678     Document Type: Article

References (34)

1. McGuire MT, Wing RR, Klem ML, Hill JO,. Behavioral strategies of individuals who have maintained long-term weight losses. Obes Res 1999; 7: 334-341.
2. Leibel RL, Rosenbaum M, Hirsch J,. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.
3. Ravussin Y, Gutman R, Diano S, et al. Effects of chronic weight perturbation on energy homeostasis and brain structure in mice. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1352-R1362.
4. Rosenbaum M, Vandenborne K, Goldsmith R, et al. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol 2003; 285: R183-R192.
5. Rosenbaum M, Kissileff HR, Mayer LE, Hirsch J, Leibel RL,. Energy intake in weight-reduced humans. Brain Res 2010; 1350: 95-102.
6. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J,. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008; 118: 2583-2591.
7. Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J,. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One 2013; 8: e59114.
8. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115: 3579-3586.
9. Kissileff HR, Thornton JC, Torres MI, et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr 2012; 95: 309-317.
10. Williamson DA, Ravussin E, Wong ML, et al. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite 2005; 45: 75-80.
11. Baicy K, London ED, Monterosso J, et al. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci U S A 2007; 104: 18276-18279.
12. Harris RB, Zhou J, Redmann SM, Jr. , et al. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998; 139: 8-19.
13. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-1575.
14. Schwartz MW, Woods SC, Porte D, Jr. , Seeley RJ, Baskin DG,. Central nervous system control of food intake. Nature 2000; 404: 661-671.
15. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174-15179.
16. Liu H, Kishi T, Roseberry AG, et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J Neurosci 2003; 23: 7143-7154.
17. Gautron L, Lee CE, Lee S, Elmquist JK,. Melanocortin-4 receptor expression in different classes of spinal and vagal primary afferent neurons in the mouse. J Comp Neurol 2012; 520: 3933-3948.
18. Gautron L, Lee C, Funahashi H, Friedman J, Lee S, Elmquist J,. Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions. J Comp Neurol 2010; 518: 6-24.
19. Ste Marie L, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD,. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci U S A 2000; 97: 12339-12344.
20. Lee M, Kim A, Chua SC, Jr. , Obici S, Wardlaw SL,. Transgenic MSH overexpression attenuates the metabolic effects of a high-fat diet. Am J Physiol Endocrinol Metab 2007; 293: E121-E131.
21. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS,. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 2002; 51: 1337-1345.
22. Hamilton BS, Doods HN,. Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obes Res 2002; 10: 182-187.
23. Yu Y, Deng C, Huang XF,. Obese reversal by a chronic energy restricted diet leaves an increased Arc NPY/AgRP, but no alteration in POMC/CART, mRNA expression in diet-induced obese mice. Behav Brain Res 2009; 205: 50-56.
24. Hahn TM, Breininger JF, Baskin DG, Schwartz MW,. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271-272.
25. Kinzig KP, Hargrave SL, Tao EE,. Central and peripheral effects of chronic food restriction and weight restoration in the rat. Am J Physiol Endocrinol Metab 2009; 296: E282-E290.
26. Korner J, Savontaus E, Chua SC, Jr. , Leibel RL, Wardlaw SL,. Leptin regulation of Agrp and Npy mRNA in the rat hypothalamus. J Neuroendocrinol 2001; 13: 959-966.
27. Melanocortin receptor-specific peptides. U.P. Office 2013;8,455,617B2.
28. Halldorsdottir S, Carmody J, Boozer CN, Leduc CA, Leibel RL,. Reproducibility and accuracy of body composition assessments in mice by dual energy x-ray absorptiometry and time domain nuclear magnetic resonance. Int J Body Compos Res 2009; 7: 147-154.
29. Hoggard N, Rayner DV, Johnston SL, Speakman JR,. Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice. J Mol Endocrinol 2004; 33: 693-703.
30. Chen AS, Metzger JM, Trumbauer ME, et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 2000; 9: 145-154.
31. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW,. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 2000; 279: R695-R703.
32. Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013; 62: 490-497.
33. Seeley RJ, Burklow ML, Wilmer KA, et al. The effect of the melanocortin agonist, MT-II, on the defended level of body adiposity. Endocrinology 2005; 146: 3732-3738.
34. Rosenbaum M, Nicolson M, Hirsch J, Murphy E, Chu F, Leibel RL,. Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab 1997; 82: 3647-3654.